drugset / Trial / NCT00334152

Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women

NCT00334152

Phase 3 Completed 515 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindPrevention

Summary

This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.

Timeline

Start
2006-03
Primary completion
2006-07
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Casopitant Small molecule 30 mg Intravenous

Indications

No indication recorded.